Stay updated on Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision label on the page updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedThe update is a minor metadata revision (Revision: v3.4.1 added; Revision: v3.4.0 removed) with no changes to study data or page content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a dedicated Locations section listing study sites in Georgia, Massachusetts, and New York (Atlanta/Emory, Boston/MGH, New York/NYU Perlmutter) and updated the record to revision v3.3.3. The HHS Vulnerability Disclosure footer link was removed.SummaryDifference0.4%

- Check91 days agoChange DetectedRevision: v3.3.2 was added in the Study Documents section, replacing v3.2.0, with no substantive changes to the study details.SummaryDifference0.1%

- Check99 days agoChange DetectedThe funding-status notice about government operating status and related links has been removed from the page, removing an informational banner about potential delays. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page.